NeuroTracker is excited to announce that they have been chosen as one of the winners in the G4A competition to partner with Bayer in developing unique digital health solutions for cancer patients. NeuroTracker was selected among 750 emerging tech companies in the digital health space.
“Our company’s “G4A Digital Health Partnerships” program paves the road for longer-term collaborations through which both parties can bring to market new solutions at the intersection of health and technology,” said Dr. Zsuzsanna Varga, who heads the Bayer G4A Digital Health Partnerships program.
The NeuroTracker science team, led by Professor Jocelyn Faubert, inventor, Co-founder and Chief Science Officer, will collaborate alongside Bayer experts.
”As a member of the Digital Therapeutics Alliance, we are excited to be forging new ground in the application of neuroscience for cancer treatment. Alongside other partnerships in the health industry, we are working to improve outcomes in oncology and other medical conditions, by combining traditional treatments with breakthroughs in neuroscience,” said Jean Castonguay, Co-founder and Head of Global Strategic Partnerships for NeuroTracker.
Read More: AiThority Interview Series with Steve Auerbach, CEO at Alegeus
For the past decade, NeuroTracker was developed and commercialized globally as a neurotechnology transfer solution for measuring, monitoring and enhancing cognitive abilities and conditions. It is now established in over 1,000 performance, wellness and medical centres around the globe, including many elite clients in sports and military performance, neurovision centres, clinics, hospitals, schools and research institutes.
Read More: The Circling Sharks Of Deep Learning — Three Mistakes To Avoid